AIM IMMUNOTECH INC (AIM) Fundamental Analysis & Valuation

NYSEARCA:AIM • US00901B3033

Current stock price

0.7286 USD
+0.05 (+7.15%)
At close:
0.72 USD
-0.01 (-1.18%)
After Hours:

This AIM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. AIM Profitability Analysis

1.1 Basic Checks

  • In the past year AIM has reported negative net income.
  • AIM had a negative operating cash flow in the past year.
  • AIM had negative earnings in each of the past 5 years.
  • AIM had a negative operating cash flow in each of the past 5 years.
AIM Yearly Net Income VS EBIT VS OCF VS FCFAIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • AIM's Return On Assets of -391.52% is on the low side compared to the rest of the industry. AIM is outperformed by 93.06% of its industry peers.
Industry RankSector Rank
ROA -391.52%
ROE N/A
ROIC N/A
ROA(3y)-132.89%
ROA(5y)-90.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AIM Yearly ROA, ROE, ROICAIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

  • AIM's Gross Margin of 71.07% is amongst the best of the industry. AIM outperforms 81.50% of its industry peers.
  • AIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AIM Yearly Profit, Operating, Gross MarginsAIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. AIM Health Analysis

2.1 Basic Checks

  • AIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AIM has been increased compared to 1 year ago.
  • The number of shares outstanding for AIM has been reduced compared to 5 years ago.
  • Compared to 1 year ago, AIM has a worse debt to assets ratio.
AIM Yearly Shares OutstandingAIM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AIM Yearly Total Debt VS Total AssetsAIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • AIM has an Altman-Z score of -162.73. This is a bad value and indicates that AIM is not financially healthy and even has some risk of bankruptcy.
  • AIM has a worse Altman-Z score (-162.73) than 94.80% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -162.73
ROIC/WACCN/A
WACC8.42%
AIM Yearly LT Debt VS Equity VS FCFAIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • AIM has a Current Ratio of 0.10. This is a bad value and indicates that AIM is not financially healthy enough and could expect problems in meeting its short term obligations.
  • AIM has a Current ratio of 0.10. This is amonst the worse of the industry: AIM underperforms 94.22% of its industry peers.
  • AIM has a Quick Ratio of 0.10. This is a bad value and indicates that AIM is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.10, AIM is not doing good in the industry: 94.22% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.1
AIM Yearly Current Assets VS Current LiabilitesAIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. AIM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 58.18% over the past year.
  • AIM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.84%.
  • The Revenue has been growing slightly by 3.96% on average over the past years.
EPS 1Y (TTM)58.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.49%
Revenue 1Y (TTM)-15.84%
Revenue growth 3Y7.99%
Revenue growth 5Y3.96%
Sales Q2Q%-25.71%

3.2 Future

  • AIM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.08% yearly.
  • The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y77.3%
EPS Next 2Y37.75%
EPS Next 3Y24.93%
EPS Next 5Y15.08%
Revenue Next Year-51.38%
Revenue Next 2Y-16.95%
Revenue Next 3Y306.65%
Revenue Next 5Y-14.87%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AIM Yearly Revenue VS EstimatesAIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 2031 2032 2033 50M 100M 150M
AIM Yearly EPS VS EstimatesAIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K -1.5K

More info and screens

Find the best growth stocksShow best growing peers

1

4. AIM Valuation Analysis

4.1 Price/Earnings Ratio

  • AIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year AIM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AIM Price Earnings VS Forward Price EarningsAIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AIM Per share dataAIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

  • AIM's earnings are expected to grow with 24.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.75%
EPS Next 3Y24.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AIM Dividend Analysis

5.1 Amount

  • No dividends for AIM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AIM Fundamentals: All Metrics, Ratios and Statistics

AIM IMMUNOTECH INC

NYSEARCA:AIM (3/13/2026, 8:09:21 PM)

After market: 0.72 -0.01 (-1.18%)

0.7286

+0.05 (+7.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-17
Earnings (Next)03-30
Inst Owners2.66%
Inst Owner Change0%
Ins Owners2.66%
Ins Owner Change0%
Market Cap3.07M
Revenue(TTM)170.00K
Net Income(TTM)-16.17M
Analysts80
Price Target22.42 (2977.13%)
Short Float %5.22%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.29%
Min EPS beat(2)38.12%
Max EPS beat(2)54.46%
EPS beat(4)4
Avg EPS beat(4)35.78%
Min EPS beat(4)13.9%
Max EPS beat(4)54.46%
EPS beat(8)5
Avg EPS beat(8)11.51%
EPS beat(12)8
Avg EPS beat(12)8.7%
EPS beat(16)8
Avg EPS beat(16)0.86%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.1%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-20.24
EYN/A
EPS(NY)-3.32
Fwd EYN/A
FCF(TTM)-2.67
FCFYN/A
OCF(TTM)-2.6
OCFYN/A
SpS0.03
BVpS-1.55
TBVpS-2.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -391.52%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.07%
FCFM N/A
ROA(3y)-132.89%
ROA(5y)-90.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.1
Altman-Z -162.73
F-Score3
WACC8.42%
ROIC/WACCN/A
Cap/Depr(3y)119.66%
Cap/Depr(5y)104.37%
Cap/Sales(3y)164.13%
Cap/Sales(5y)265.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.49%
EPS Next Y77.3%
EPS Next 2Y37.75%
EPS Next 3Y24.93%
EPS Next 5Y15.08%
Revenue 1Y (TTM)-15.84%
Revenue growth 3Y7.99%
Revenue growth 5Y3.96%
Sales Q2Q%-25.71%
Revenue Next Year-51.38%
Revenue Next 2Y-16.95%
Revenue Next 3Y306.65%
Revenue Next 5Y-14.87%
EBIT growth 1Y47.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year372.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.07%
OCF growth 3YN/A
OCF growth 5YN/A

AIM IMMUNOTECH INC / AIM Fundamental Analysis FAQ

What is the ChartMill fundamental rating of AIM IMMUNOTECH INC (AIM) stock?

ChartMill assigns a fundamental rating of 1 / 10 to AIM.


What is the valuation status for AIM stock?

ChartMill assigns a valuation rating of 1 / 10 to AIM IMMUNOTECH INC (AIM). This can be considered as Overvalued.


Can you provide the profitability details for AIM IMMUNOTECH INC?

AIM IMMUNOTECH INC (AIM) has a profitability rating of 1 / 10.


What is the expected EPS growth for AIM IMMUNOTECH INC (AIM) stock?

The Earnings per Share (EPS) of AIM IMMUNOTECH INC (AIM) is expected to grow by 77.3% in the next year.